Event Calendar

Petach Tikva, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it will host a virtual Investor Day on Wednesday, October 28, 2026, at 11:30 a.m. ET.

During the event, PolyPid’s management team will outline the Company’s “PolyPid 2030” long-term growth and pipeline strategy. Management will also provide an update on D-PLEX₁₀₀, the Company’s lead product candidate for the prevention of colorectal surgical site infections, whose New Drug Application (“NDA”) is under U.S. Food and Drug Administration (“FDA”) Priority Review with a Prescription Drug User Fee Act (“PDUFA”) goal date of November 28, 2026, and will introduce PD01B, a new product candidate based on PolyPid’s Kynatrix™ delivery technology, being developed for the treatment of diabetic foot infections.

The event will feature Key Opinion Leader (“KOL”) Warren S. Joseph, DPM, FIDSA, a leading podiatric physician and a specialist in the treatment of lower extremity infections, widely recognized as an authority on the diagnosis and treatment of diabetic foot infections, who will discuss the clinical burden of diabetic foot infections, the limitations of current treatment approaches, and the potential role of locally delivered, controlled-release antibiotic therapy in this setting. A live question-and-answer session with Dr. Joseph and PolyPid’s management team will follow the formal presentations.

To ensure you are connected prior to the beginning of the event, PolyPid suggests registering a minimum of 5 minutes before the start of the event. For those not planning to ask a question of the Company’s management or Dr. Joseph, the Company recommends listening via the webcast.

Investor Day Dial-In and Webcast Information: